Loading...
Loading...
PHIO| Name | Value |
|---|---|
| Revenues | 30.0K |
| Cost of Revenue | 43.0K |
| Gross Profit | -13.0K |
| Operating Expense | 1,730.0K |
| Operating I/L | -1,773.0K |
| Other Income/Expense | 4.0K |
| Interest Income | 0.0K |
| Pretax | -1,895.0K |
| Income Tax Expense | 51.0K |
| Net Income/Loss | -1,895.0K |
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States, focusing on targeting tumor and immune cells by regulating genes of the immune system. The company's INTASYL therapeutic platform includes PH-762, which activates immune cells to recognize and kill cancer cells, PH-894 that silences the epigenetic protein BRD4, and PH-804 that targets the suppressive immune receptor TIGIT. These products are designed for use in adoptive cell transfer (ACT) for cancer immunotherapy. Phio Pharmaceuticals Corp. also collaborates with AgonOx Inc. on the clinical development of novel T cell-based cancer immunotherapies.
